Centocor, Inc. and Schering-Plough have submitted a Marketing Authorization Application (MAA) to the EMEA requesting the approval of golimumab (CNTO 148) as a monthly intravenous (IV) infusion therapy for adults with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The initial submission and Phase III development programs for golimumab, an anti-tumor necrosis factor (TNF)- alpha monoclonal antibody, marks the first time that an MAA has been submitted for three unique disease...